RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
149 hedge funds and large institutions have $884M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 40 increasing their positions, 50 reducing their positions, and 34 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
20% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 50
70% less call options, than puts
Call options by funds: $21.3M | Put options by funds: $70.1M
Holders
149
Holding in Top 10
2
Calls
$21.3M
Puts
$70.1M
Top Buyers
| 1 | +$64.7M | |
| 2 | +$49.1M | |
| 3 | +$40.6M | |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$19.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.03M |
Top Sellers
| 1 | -$72.9M | |
| 2 | -$35.2M | |
| 3 | -$13.2M | |
| 4 |
Millennium Management
New York
|
-$12.1M |
| 5 |
DFO
Duquesne Family Office
New York
|
-$11.4M |